Advance Market Commitments: A Policy to Stimulate Investment in Vaccines for Neglected Diseases

  title={Advance Market Commitments: A Policy to Stimulate Investment in Vaccines for Neglected Diseases},
  author={Owen Matthew Barder and Michael Kremer and Heidi L. Williams},
  journal={The Economists' Voice},
Why are millions dying of neglected diseases without vaccines, and is there a way to cheaply change that? Owen Barder, Michael Kremer and Heidi Williams advocate a proposal--Advance Market Commitments--that the G8 finance ministers plan to pilot in 2006. 
Vaccines for Development
Five innovative policy measures are being implemented to address these challenges: performance-based grants, a global vaccine purchasing fund, the new International Finance Facility for Immunization
Vaccines and global health: In search of a sustainable model for vaccine development and delivery
Conquering diseases such as tuberculosis, HIV, malaria, and Ebola, as well as illnesses caused by multidrug-resistant pathogens, requires considerable investment and a new sustainable model of vaccine development involving close collaborations between public and private sectors.
A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics
A decision framework focuses on addressing market failures that result in limited investment, public health priorities regarding antibiotic stewardship and patient access, and implementation constraints and operational realities and allows policy makers to tailor an antibiotic incentive package that suits a country’s health system structure and needs.
R&D in Vaccines Targeting Neglected Diseases: An Exploratory Case Study Considering Funding for Preventive Tuberculosis Vaccine Development from 2007 to 2014
Taking into account the dynamics of innovation currently seen at work in the vaccine sector, a highly concentrated market dominated by few multinational pharmaceutical companies, it is felt that global PDP models can play an important role throughout the vaccine development cycle.
Access to medicines, market failure and market intervention: A tale of two regimes
It is argued that a parallel ‘pro-access regime’ has developed in order to correct some of the most high-profile issues associated with a dysfunctional global pharmaceutical market, especially problems regarding price and innovation that have been exacerbated by stringent global patent rights on new drugs.
The ethics and economics of pharmaceutical pricing.
Advances in economic research have increased the sharpness and focus of the ethically based calls to increase access by modifying patent protection and reducing prices and in some cases, research supports ethical arguments for broader access.
Making Medicines in Kenya, Tanzania, and Uganda in the AIDS Era
Can foreign aid help the development of local industrial production in poor countries? Studies offer a range of reasons why foreign aid is doomed to fail. Anthropologists highlight the exploitative
Of Marshallian Scissors & Blades: Demand Shocks, Import Exposure, and Innovation in Indian Influenza-Vaccine Markets
This paper examines the relationship between exogenous shocks in the demand for pharmaceuticals and the structure of India?s vaccine markets. Using a novel dataset of detailed purchasing information


Vaccine advance-purchase agreements for low-income countries: practical issues.
Practical issues are identified that the public health and policy community should consider further in the design of an advance-purchase commitment for vaccines for diseases concentrated in low-income countries.
Are pharmaceuticals cost-effective? A review of the evidence.
A new database of 228 published cost-utility analyses sheds light on the issue, finding that some drugs do save money or are cost-effective, but the issue depends critically on the context in which the drug is used and the intervention with which it is compared.
Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases
It is concluded that a commitment to purchasing vaccines could develop within low-income countries and that developing countries now have the right to produce drugs protected by the patent holder and to grant compulsory licenses to home manufacturers through this agreement.
PneumoADIP: an example of translational research to accelerate pneumococcal vaccination in developing countries.
If successful, PneumoADIP will reduce the uncertainty of demand, allow appropriate planning of supply, and achieve adequate and affordable availability of product for the introduction of pneumococcal vaccines.
Access to essential drugs in poor countries: a lost battle?
The problems of access to quality drugs for the treatment of diseases that predominantly affect the developing world are focused on: poor-quality and counterfeit drugs; lack of availability of essential drugs due to fluctuating production or prohibitive cost; need to develop field-based drug research to determine optimum utilization; and potential consequences of recent World Trade Organization agreements on the availability of old and new drugs.
Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry
This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutical innovation. Focusing on exogenous changes driven by U.S. demographic trends, we find that a 1
Disease Control Priorities in Developing Countries
It is found that poorer or ethnic and religious minorities are more likely to visit a public healthcare provider than a private provider and distance to facilities and the level of dissatisfaction with public providers within the community have a strong negative influence on a household’s choice of public healthcare facilities.
Global alliance for vaccines and immunization (GAVI).
  • Medicine
    Indian journal of medical sciences
  • 2001
Robert and the Expanded Programme on Immunization Team Global Immunization
  • Annual Review of Public Health
  • 1992